Hybrid coronary revascularization in multivessel coronary artery disease: a systematic review

Future Cardiol. 2022 Mar;18(3):219-234. doi: 10.2217/fca-2020-0244. Epub 2022 Jan 10.

Abstract

Aim: Hybrid coronary revascularization (HCR) for multivessel coronary artery disease (CAD) integrates coronary artery bypass grafting (CABG) and percutaneous intervention in a planned revascularization strategy. This systematic review summarizes the state of this art of this technique. Methods: Major databases searched until October 2021. Results: The available literature on HCR includes three randomized trials, ten meta-analysis and 27 retrospective studies. The greatest benefits are observed in patients with low-to-intermediate risk and less complex coronary anatomy; highly complex disease and the presence of risk factors favored conventional CABG in terms of adverse events and survival. Conclusion: HCR is an interesting approach for multivessel CAD but should not be considered a 'one-size-fits-all' procedure. Further studies will specify the subset of patients likely to benefit most from this hybrid approach.

Keywords: coronary artery bypass grafting; hybrid coronary revascularization; myocardial revascularization; percutaneous coronary intervention; systematic review.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Coronary Artery Bypass / adverse effects
  • Coronary Artery Bypass / methods
  • Coronary Artery Disease* / etiology
  • Humans
  • Percutaneous Coronary Intervention* / methods
  • Retrospective Studies
  • Treatment Outcome